PJPing Jin

Ping Jin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ping Jin has a total of 180 co-authors. Here are the top co-authors by number of shared publications:

  • Qin Zhang

    Department of endocrinology, Central South University Third Xiangya Hospital, Changsha, China

    9 shared publications
  • Gaopeng Guan

    Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha, China

    5 shared publications
  • Jie Liu

    Department of endocrinology, Central South University Third Xiangya Hospital, Changsha, China

    5 shared publications
  • Wen-Mu Hu

    Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province, China

    5 shared publications
  • Jinjing Wan

    Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha, China

    4 shared publications
  • Liling Zhao

    Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013, China.

    4 shared publications

Latest Publications

  • Open Access

    UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial

    by Zhiguang Zhou, Zhifeng Cheng, Ping Jin, Guoping Yang, Haifang Wang, Bimin Shi, Qijuan Dong, Xiaoxia Shi, Xiaoguang Shi, Hongyan Shu, et al.

  • Safety, Pharmacokinetics and Pharmacodynamics of the GLP ‐1/ GIP / GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo‐Controlled Phase 1a/1b Study

    by Guo‐Ping Yang, Ya‐Xin Liu, Jin‐Lian Xie, Shan Zeng, Jing Xiong, Wei Ling, Hai‐Yan Zhang, Tao Su, Yu‐Xiu Xu, Liang Huang, et al.

    Aims: UBT251 is a novel triple agonist peptide targeting the glucagon‐like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic polypeptide (GIP) and glucagon receptors. This first‐in‐human Phase 1a/1b study evaluated the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of UBT251. Materials and Methods: This randomized, double‐blind, placebo‐controlled study consisted of two clinical trials. The Phase 1a study was a single‐ascending‐dose trial, in which participants received a single subcutaneous injection of UBT251 at doses ranging from 0.1 to 4.5 mg. The Phase 1b study was a multiple‐ascending‐dose trial conducted in participants with overweight or obesity without diabetes. UBT251 was administered once weekly by subcutaneous injection for 12 consecutive weeks. Safety and tolerability were the primary endpoints. Results: UBT251 was generally well tolerated, with laboratory investigations, decreased appetite and gastrointestinal adverse events being the most common adverse effects. In participants with overweight or obesity, once‐weekly subcutaneous injections of UBT251 at doses of 1, 3 and 6 mg for 12 weeks led to a mean body weight reduction of 8.96–13.48 kg, compared with the 1.57 kg increase observed in the placebo group. Following single and multiple dosing, UBT251 exhibited approximately linear pharmacokinetics across the 1.0–6.0 mg dose range. UBT251 treatment also demonstrated favourable metabolic effects, including reductions in fasting plasma glucose, haemoglobin A1c and lipid parameters. Conclusions: UBT251 demonstrated an acceptable safety profile and predictable pharmacokinetic properties, accompanied by substantial weight reduction and meaningful metabolic improvements. These findings strongly support the continued clinical development of UBT251 as a potential therapeutic option for obesity and type 2 diabetes. Trial Registration: ChiCTR2600116148 and ChiCTR2600123803 ( https://www.chictr.org.cn/ )


  • [A rare case of Rosai-Dorfman disease involving the pituitary stalk and presenting initially with diabetes insipidus].

    by Lusha Li, Honghui He, Shaoli Zhao, Ling Chu, Ping Jin

    Rosai-Dorfman disease (RDD) is a rare form of non-Langerhans cell histiocytosis. In August 2024, a 38-year-old man was admitted to the Department of Endocrinology, The Third Xiangya Hospital of Central South University. He initially presented with diabetes insipidus, and his condition gradually progressed over a 15-year disease course, eventually leading to panhypopituitarism. Imaging examinations revealed marked thickening of the pituitary stalk, 2 meningioma-like dural nodules, multiple osteolytic lesions, mild interstitial pneumonia, and urinary system involvement. RDD was confirmed by a pituitary stalk biopsy, and a BRAF V600E mutation was identified. The patient subsequently received targeted therapy with the BRAF inhibitor dabrafenib in combination with pituitary hormone replacement therapy. Follow-up brain magnetic resonance imaging after 8 months of treatment demonstrated a reduction in pituitary stalk thickening and complete disappearance of the 2 meningioma-like dural nodules. The patient's quality of life also improved substantially. This retrospective analysis of the case may assist clinicians in determining the etiology and differential diagnosis of pituitary stalk thickening and enhance awareness of RDD as a rare disease.

  • Open Access

    Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

    by Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan

    Aim: This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods: In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐controlled trial, 64 Chinese adults with T2DM were randomly assigned to BGM0504 5 mg ( n = 12), 10 mg ( n = 12), 15 mg ( n = 12), placebo ( n = 12) or semaglutide 1 mg ( n = 16). All participants received their assigned dose once weekly for 12 weeks. The primary endpoint was the change in HbA1c from baseline, and secondary endpoints included fasting plasma glucose (FPG), 2‐h plasma glucose (2 h PG) and body weight. Safety was assessed through adverse events, laboratory tests and vital signs. Results: At Week 12, the mean changes in HbA1c from baseline were −1.72% for the 5 mg dose, −1.94% for the 10 mg dose, −2.48% for the 15 mg dose, −1.43% for 1 mg semaglutide and 0.28% for placebo, with the treatment differences versus placebo (LSM) ranging from −1.82% to −2.56% (all p < 0.05). The proportion of participants achieving HbA1c < 6.5% or < 7.0% increased in a dose‐dependent manner. BGM0504 also shows a signal for lowering FPG, 2 h PG and body weight (all p < 0.05), with the 15 mg dose showing superior weight reduction to semaglutide. Pharmacokinetics analysis confirmed a linear exposure–response relationship. All doses were well tolerated, with mostly mild adverse events. Conclusion: BGM0504 shows a signal reduction for HbA1c, FPG, 2 h PG and body weight in Chinese adults with T2DM. The 12‐week treatment with BGM0504 was safe and well‐tolerated, with the 15 mg dose showing the most substantial effects.


  • Open Access

    Effect of Lifestyle Intervention on the Mobilization of Fat Depots and Organ Iron Deposition in Individuals with Obesity: A Prospective Study

    by Hong Liu, Junhong Duan, Gaopeng Guan, Pengfei Rong, Ping Jin

    Purpose: To investigate how lifestyle interventions alter fat distribution and organ-specific iron deposition in individuals with obesity, and whether these changes can serve as indicators of glycemic remission in obese patients with dysglycemia. Methods: This prospective study included individuals with obesity who participated in a 6-month lifestyle intervention, which comprised a caloric-restricted balanced diet and an exercise regimen. Ultimately, 104 participants completed the follow-up phase. Magnetic resonance imaging (MRI) was utilized to monitor the dynamics of fat mobilization and organ iron deposition at baseline and 6-month follow-up. Correlation analysis, logistic regression, and receiver operating characteristic (ROC) curve analysis were employed to examine the relationships between regional fat distribution, organ iron deposition, and glycemic improvement. Results: Initially, the 104 participants were divided into three categories: normal glucose regulation (NGR, n=41), prediabetes (n=23), and type 2 diabetes mellitus (T2DM, n=40). After a 6-month lifestyle change, the number of patients with T2DM and prediabetes decreased, and those with NGR increased. There were also notable decreases in liver and pancreatic fat, as well as visceral and subcutaneous fat, with the largest decrease in liver fat (− 43.2%) among obese participants. There were also reductions in liver and pancreatic iron deposition after intervention. ROC curve analysis revealed that the change in liver fat was the best indicator of diabetes remission among obese participants, with an area under the curve of 0.819 (95% confidence interval [CI]: 0.681– 0.957). Notably, liver fat reduction ≥ 38.8% predicted diabetes remission (OR=2.5, 95% CI:1.59– 5.60) in individuals with obesity. Conclusion: Lifestyle intervention can effectively reduce ectopic fat and iron overload in individuals with obesity. The extent of hepatic fat mobilization has emerged as the most significant indicator of diabetes remission in individuals with obesity, potentially serving as a pivotal focus for future therapeutic interventions.


  • Open Access

    A type 1 diabetes genetic risk score discriminates between type 1 diabetes and type 2 diabetes in a Chinese population

    by Jingyi Hu, Guozhi Jiang, Jiabi Qin, Shuoming Luo, Baoqi Fan, Zhiguo Xie, Raymond Wan, Xia Li, Claudia H. T. Tam, Zhenqian Wang, et al.

    Aims/hypothesis: We aimed to generate a population-specific type 1 diabetes genetic risk score (GRS) and assess whether it could improve discrimination between type 1 diabetes and type 2 diabetes in a Chinese population. Methods: We performed a genome-wide association analysis on 1303 individuals with type 1 diabetes and 2236 control individuals. An independent replication cohort of 501 individuals with type 1 diabetes and 853 control individuals was used to validate the top common variant associations. HLA typing data were used to identify tag SNPs for DQA1-DQB1 haplotypes. We integrated significant signals to construct a Chinese type 1 diabetes GRS (C-GRS). The accuracy of the C-GRS was tested in an independent validation cohort consisting of 262 individuals with type 1 diabetes, 1080 individuals with type 2 diabetes and 208 control individuals. Results: We identified a variant, rs10232170, in BMPER as a possible novel type 1 diabetes locus (p=9.897×10−9). We identified tag SNPs for 13 DQA1-DQB1 haplotypes and 12 non-DQA1-DQB1 loci. Integrating 33 significant SNPs from HLA and non-HLA regions, C-GRS demonstrated high discriminative power for type 1 diabetes (AUC=0.876). It was tested in an independent validation cohort and showed high discrimination (AUC 0.871 for type 1 diabetes vs control group, 0.869 for type 1 diabetes vs type 2 diabetes). The C-GRS outperformed a European-derived GRS (0.871 vs 0.773, and 0.869 vs 0.793, respectively). Conclusions/interpretation: A type 1 diabetes C-GRS comprising 33 SNPs was highly discriminative of type 1 diabetes risk in the Chinese population and could aid in discriminating between type 1 diabetes and type 2 diabetes. This study highlights the potential of genetic information in improving prediction and precision diagnosis of type 1 diabetes in the Chinese population. Data availability: The raw sequencing data and summary statistics of genomic DNA derived from human samples have been deposited at the China National Center for Bioinformation (https://ngdc.cncb.ac.cn/omix) under accession number PRJCA023730. Graphical


  • Open Access

    Efficacy of Polyethylene Glycol Loxenatide in Combination with Basal Insulin in Patients with Type 2 Diabetes Mellitus: A Retrospective Real-World Study

    by Xiaohuan Liu, Ying Zhang, Li-Ling Zhao, Yale Duan, Zhizhen Hu, Liya Bao, Ping Jin

    Introduction Patients with type 2 diabetes mellitus (T2DM) who cannot achieve normal glycosylated hemoglobin (HbA1c) levels are sometimes given the combined therapeutic regimen of polyethylene glycol loxenatide (PEG-Loxe) + basal insulin. The aim of this study was to investigate the efficacy and safety of PEG-Loxe combined with basal insulin in patients with T2DM. Methods This retrospective, real-world study included patients with T2DM aged ≥ 18 years for whom basal insulin therapy was ineffective, whose HbA1c levels were between 7.0% and 11.0%, and who were on either continued basal insulin dose adjustment or who had received PEG-Loxe + basal insulin combined therapy for at least 24 weeks. The primary endpoint was change in HbA1c level after 24 weeks treatment. Secondary endpoints included HbA1c achievement target rate, change in fasting plasma glucose and body weight, respectively, and change in HbA1c stratified by sex, age, disease duration, and baseline HbA1c level. Results Overall, 307 patients were identified. After propensity score matching, 44 patients each were included in the basal insulin and PEG-Loxe + basal insulin group. After 24 weeks, a significant difference in Hb1Ac reduction between the groups (P = 0.003) was observed. Also, patients treated with PEG-Loxe + basal insulin combined therapy experienced greater body weight reduction compared those treated with basal insulin only (intergroup difference: − 3.2 kg; 95% confidence interval [95% CI] − 5.4, − 1.0]; P = 0.005). There was a significant intergroup difference in weight reduction in patients with body mass index ≥ 28 kg/m2 (− 8.4 kg; 95% CI − 13.9, − 3.0; P = 0.004). HbA1c levels in female patients aged < 65 years with HbA1c ≥ 8.5% and with a disease duration ≥ 10 years were significantly different between the two treatment groups (P < 0.005). Hypoglycemic events occurred in 10.4% of patients treated with PEG-Loxe + basal insulin with no cases of level 3 hypoglycemia. Conclusion PEG-Loxe + basal insulin combined therapy was safe and effective in patients with T2DM who did not achieve optimal glycemic control with insulin therapy alone. Trial Registration ClinicalTrials.gov identifier: ChiCTR2400086699.


  • Open Access

    NFAT5 exacerbates β-cell ferroptosis by suppressing the transcription of PRDX2 in obese type 2 diabetes mellitus

    by Gaopeng Guan, Jie Liu, Qin Zhang, Meiqi He, Hong Liu, Ke Chen, Xinxing Wan, Ping Jin

    Pancreatic β-cell damage is a critical pathological mechanism in the progression of obese type 2 diabetes mellitus (T2DM). However, the exact underlying mechanism remains unclear. We established an obese T2DM mouse model via high-fat diet feeding. The protein expression profiles of pancreatic tissues from normal and obese T2DM mice were analyzed, revealing that nuclear factor of activated T cells 5 (NFAT5) and ferroptosis are potential mediators and mechanisms of β-cell damage in obese T2DM mice. In vitro, high glucose and palmitate treatment resulted in increased NFAT5 expression and nuclear translocation in MIN6 cells. Inhibition of NFAT5 expression by shRNA significantly reduced ferroptosis and improved the reduction in insulin secretion in palmitic acid and high glucose (PG)-treated MIN6 cells. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays confirmed the ability of NFAT5 to bind to the peroxiredoxin 2 (PRDX2) promoter, leading to the downregulation of PRDX2 transcription. Subsequent rescue experiments confirmed that NFAT5 is involved in PG-induced ferroptosis in MIN6 cells by inhibiting the expression of PRDX2. Finally, we demonstrated that the use of the AAV8-RIP2-miR30-shNFAT5 vector to specifically inhibit the expression of NFAT5 in β-cells significantly diminishes ferroptosis in obese T2DM mice, thereby increasing insulin secretion and improving abnormal glucose tolerance. These findings collectively highlight the therapeutic potential of targeting NFAT5 in β cells to counteract obesity-induced T2DM.